PCM
MNPR icon

Prelude Capital Management’s Monopar Therapeutics MNPR Stock Holding History

Prelude Capital Management’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-302
Closed -$25K – 1813
2019
Q4 		$25K Buy
+302
New +$31.5K ﹤0.01% 1537

Other funds holding MNPR

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Prelude Capital Management's MNPR Position: Q1 2020 in Review

Prelude Capital Management sold out of Monopar Therapeutics (MNPR) in Q1 2020, closing a stake of 302 shares — an estimated $25K sold.

Prelude Capital Management first reported a position in MNPR in Q4 2019 and held it in 1 quarter. The position peaked at $25K in Q4 2019. 7 funds tracked by Wall St. Rank hold MNPR as of Q1 2020.

  • Prelude Capital Management reported no remaining Monopar Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Prelude Capital Management sold 302 Monopar Therapeutics shares in Q1 2020, an estimated $25K.
  • Prelude Capital Management first reported a position in Monopar Therapeutics in Q4 2019 and held it in 1 quarter.
  • Prelude Capital Management's Monopar Therapeutics position peaked at $25K in Q4 2019.
  • 7 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2020.

Based on Prelude Capital Management's 13F filing for Q1 2020, filed 15 May 2020.